Trial Outcomes & Findings for Lundbeck TOMs Orthostatic Hypotension (NCT NCT04510922)
NCT ID: NCT04510922
Last Updated: 2022-09-26
Results Overview
Orthostatic Hypotension Symptom Assessment (OHSA; Range: 0-10) and Orthostatic Hypotension Daily Activities Scale (OHDAS; Range: 0-10) 10 items measured on a Likert-scale with 10 being the worst possible score.
COMPLETED
PHASE4
9 participants
1 month
2022-09-26
Participant Flow
Only 9 participants completed the study.
Participant milestones
| Measure |
Droxidopa
100-600mg droxidopa TID
Droxidopa 100 MG \[Northera\]: droxidopa taken three times a day titrated up to a maximum of 600 mg.
|
|---|---|
|
Overall Study
STARTED
|
9
|
|
Overall Study
COMPLETED
|
9
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Droxidopa
n=9 Participants
100-600mg droxidopa TID
Droxidopa 100 MG \[Northera\]: droxidopa taken three times a day titrated up to a maximum of 600 mg.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=9 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
3 Participants
n=9 Participants
|
|
Age, Categorical
>=65 years
|
6 Participants
n=9 Participants
|
|
Age, Continuous
|
67.3 years
STANDARD_DEVIATION 8 • n=9 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=9 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=9 Participants
|
|
Region of Enrollment
United States
|
9 participants
n=9 Participants
|
PRIMARY outcome
Timeframe: 1 monthOrthostatic Hypotension Symptom Assessment (OHSA; Range: 0-10) and Orthostatic Hypotension Daily Activities Scale (OHDAS; Range: 0-10) 10 items measured on a Likert-scale with 10 being the worst possible score.
Outcome measures
| Measure |
Droxidopa
n=9 Participants
100-600mg droxidopa TID
Droxidopa 100 MG \[Northera\]: droxidopa taken three times a day titrated up to a maximum of 600 mg.
|
|---|---|
|
Orthostatic Hypotension Questionnaire (OHQ) Score
|
4.6 score on a scale
Standard Deviation 1.9
|
PRIMARY outcome
Timeframe: 6 weekshe Tinetti assessment tool is an easily administered task-oriented test that measures an older adult's gait and balance abilities. Scoring: Items are scored either "0-1" or "0-2". "0" indicates the highest level of impairment, whereas a higher score (1 or 2) indicates the individuals independence. There were 17 tasks (one task split into two sub-items and scored twice) that the scores were summed for a highest possible score of 28 (10 items scored on a 0-1 scale, and 8 items scored on a 0-2 scale). The Tinetti assessment was compared pre- and post- 6 week medication dosing.
Outcome measures
| Measure |
Droxidopa
n=9 Participants
100-600mg droxidopa TID
Droxidopa 100 MG \[Northera\]: droxidopa taken three times a day titrated up to a maximum of 600 mg.
|
|---|---|
|
Tinetti Score
|
13.4 score on a scale
Standard Deviation 2.07
|
PRIMARY outcome
Timeframe: 6 weeksThe Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living including mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The scale consists of 39 items ranked on a 5-point ordinal scale (Never=0, Occasionally=1, Sometimes=2, Often=3, Always=4). Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better Quality of Life. Dimension score = sum of scores of each item in the dimension divided by the maximum possible score of all the items in the dimension, multiplied by 100. Overall score = sum of dimension total scores divided by 8. Scores were compared pre- and post- 6 weeks dosing with medication.
Outcome measures
| Measure |
Droxidopa
n=9 Participants
100-600mg droxidopa TID
Droxidopa 100 MG \[Northera\]: droxidopa taken three times a day titrated up to a maximum of 600 mg.
|
|---|---|
|
PDQ-39 Score
|
31 score on a scale
Standard Deviation 18.1
|
PRIMARY outcome
Timeframe: 1 monthMeasured in cm
Outcome measures
| Measure |
Droxidopa
n=9 Participants
100-600mg droxidopa TID
Droxidopa 100 MG \[Northera\]: droxidopa taken three times a day titrated up to a maximum of 600 mg.
|
|---|---|
|
Gait Analysis - Stride Length
|
60.3 cm
Standard Deviation 9
|
PRIMARY outcome
Timeframe: 6 weeksUsing a gait mat, participants were instructed to walk self-paced along the mat. The sensors in the mat automatically extracted the percentage of time a participant stood on a single leg. The output was compared pre- and post- 6 week dosing with study medication.
Outcome measures
| Measure |
Droxidopa
n=9 Participants
100-600mg droxidopa TID
Droxidopa 100 MG \[Northera\]: droxidopa taken three times a day titrated up to a maximum of 600 mg.
|
|---|---|
|
Gait Analysis - Single Leg Stance Time
|
34.6 percentage of time
Standard Deviation 2
|
PRIMARY outcome
Timeframe: 6 weeksUsing a gait mat, participants were instructed to walk self-paced on the mat, turn around, and walk back. Their velocity was measured in cm/sec. This output was compared pre- and post- 6 week dosing with study medication.
Outcome measures
| Measure |
Droxidopa
n=9 Participants
100-600mg droxidopa TID
Droxidopa 100 MG \[Northera\]: droxidopa taken three times a day titrated up to a maximum of 600 mg.
|
|---|---|
|
Gait Analysis - Gait Velocity
|
112.1 cm/sec
Standard Deviation 17.2
|
PRIMARY outcome
Timeframe: 6 weeksUsing a gait mat, postural sway was measured in cm on the X-axis while participants were asked to stand eyes open and eyes closed for 30 seconds. This output was compared pre- and post- 6 weeks dosing with study medication.
Outcome measures
| Measure |
Droxidopa
n=9 Participants
100-600mg droxidopa TID
Droxidopa 100 MG \[Northera\]: droxidopa taken three times a day titrated up to a maximum of 600 mg.
|
|---|---|
|
Postural Analysis - Postural Sway
|
35.8 cm
Standard Deviation 51.2
|
Adverse Events
Droxidopa
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place